Antibe Therapeutics (TSX:ATE) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Debt-to-Equity?

Antibe Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Antibe Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Antibe Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$25.94 Mil. Antibe Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Antibe Therapeutics's Debt-to-Equity or its related term are showing as below:

During the past 12 years, the highest Debt-to-Equity Ratio of Antibe Therapeutics was 1.30. The lowest was 0.00. And the median was 0.36.

TSX:ATE's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Antibe Therapeutics Debt-to-Equity Historical Data

The historical data trend for Antibe Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Debt-to-Equity Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.28

0.64

0.01

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Antibe Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Antibe Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Debt-to-Equity falls into.

Antibe Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Antibe Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	40.166
	=	0.00

Antibe Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	25.937
	=	0.00

Antibe Therapeutics (TSX:ATE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Antibe Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Executives

Daniel Marcel Legault	Senior Officer
Alain Wilson	Senior Officer
John Lawrence Wallace	Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis	Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines